Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBG9HI)

Drug Name

AB023 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
End-stage renal disease	GB61.5	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor XI (F11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A186	DMHJ0EB	Clotting disorder	3B4Z	IND submitted	[3]
Asundexian	DMLZMU2	Ischemic stroke	8B11.5Z	Phase 3	[4]
Abelacimab	DM09YTN	Atrial fibrillation	BC81.3	Phase 2	[5]
MK-2060	DM79A32	Thrombosis	DB61-GB90	Phase 2	[6]
EP-7041	DMV0MHI	Thrombosis	DB61-GB90	Phase 1	[7]
A336	DMVQG8G	Clotting disorder	3B4Z	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03097341) Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects. U.S. National Institutes of Health.
2	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.
3	Clinical pipeline report, company report or official report of Klus Pharma
4	Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022 Jun;20(6):1400-1411.
5	Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2022 Feb;20(2):307-315.
6	Clinical pipeline report, company report or official report of MSD
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)